
|Videos|November 1, 2017
Dr. Chan Discusses Cabozantinib for the Treatment of NETs
Author(s)Jennifer Chan MD, MPH
Jennifer Chan, MD, MPH, clinical director, Program in Carcinoid and Neuroendocrine Tumors, Dana-Farber Cancer Institute, discusses a study exploring cabozantinib (Cabometyx) for the treatment of patients with advanced carcinoid and pancreatic neuroendocrine tumors.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































